Laurencin | CAS#3442-58-8 | sea hare extract

MedKoo Cat#: 559048 | Name: Laurencin

Description:

WARNING: This product is for research use only, not for human or veterinary use.

Laurencin is an extract of sea hare, Aplysia dactylomela.

Chemical Structure

Laurencin

CAS#3442-58-8

Theoretical Analysis

MedKoo Cat#: 559048

Name: Laurencin

CAS#: 3442-58-8

Chemical Formula: C17H23BrO3

Exact Mass: 354.0831

Molecular Weight: 355.27

Elemental Analysis: C, 57.47; H, 6.53; Br, 22.49; O, 13.51

Price and Availability

This product is currently not in stock but may be available through custom synthesis. To ensure cost efficiency, the minimum order quantity is 1 gram. The estimated lead time is 2 to 4 months, with pricing dependent on the complexity of the synthesis (typically high for intricate chemistries). Quotes for quantities below 1 gram will not be provided. To request a quote, please click the button below. Note: If this product becomes available in stock in the future, pricing will be listed accordingly.

Bulk Inquiry

Related CAS #

No Data

Synonym

Laurencin; NSC 122763; NSC-122763; NSC122763;

IUPAC/Chemical Name

(E)-1-((2R,7S,8R,Z)-7-bromo-8-ethyl-3,6,7,8-tetrahydro-2H-oxocin-2-yl)hex-3-en-5-yn-1-yl acetate

InChi Key

ZFYWONYUPVGTQJ-MLQIYZSFSA-N

InChi Code

InChI=1S/C17H23BrO3/c1-4-6-7-11-16(20-13(3)19)17-12-9-8-10-14(18)15(5-2)21-17/h1,6-9,14-17H,5,10-12H2,2-3H3/b7-6+,9-8-/t14-,15+,16?,17+/m0/s1

SMILES Code

C#C/C=C/CC(OC(C)=O)[C@@H]1O[C@H](CC)[C@@H](Br)C/C=C\C1

Appearance

Solid powder

Purity

>98% (or refer to the Certificate of Analysis)

Shipping Condition

Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition

Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility

Soluble in DMSO

Shelf Life

>3 years if stored properly

Drug Formulation

This drug may be formulated in DMSO

Stock Solution Storage

0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code

2934.99.03.00

More Info

Instruction

View handling instruction

Preparing Stock Solutions

The following data is based on the product molecular weight 355.27 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
1 mM	1.15 mL	5.76 mL	11.51 mL
5 mM	0.23 mL	1.15 mL	2.3 mL
10 mM	0.12 mL	0.58 mL	1.15 mL
50 mM	0.02 mL	0.12 mL	0.23 mL

1: Yoshikawa K, Otsu M, Ito T, Asakawa Y, Kawano S, Hashimoto T. Aromatic constituents of Cymbidium Great Flower Marie Laurencin and their antioxidative activity. J Nat Med. 2013 Jan;67(1):217-21. doi: 10.1007/s11418-012-0653-z. Epub 2012 Mar 17. PubMed PMID: 22427197. 2: Suzuki M, Takahashi Y, Nakano S, Abe T, Masuda M, Ohnishi T, Noya Y, Seki K. An experimental approach to study the biosynthesis of brominated metabolites by the red algal genus Laurencia. Phytochemistry. 2009 Jul-Aug;70(11-12):1410-5. doi: 10.1016/j.phytochem.2009.07.038. Epub 2009 Sep 4. PubMed PMID: 19733868. 3: Adsool VA, Pansare SV. An enantioselective approach to (+)-laurencin. Org Biomol Chem. 2008 Jun 7;6(11):2011-5. doi: 10.1039/b803973a. Epub 2008 Apr 11. PubMed PMID: 18480916. 4: Li J, Suh JM, Chin E. Expedient enantioselective synthesis of the δ4-oxocene cores of (+)-laurencin and (+)-prelaureatin (‡). Org Lett. 2010 Nov 5;12(21):4712-5. doi: 10.1021/ol1021965. PubMed PMID: 20919723. 5: Kuyinu EL, Narayanan G, Nair LS, Laurencin CT. Animal models of osteoarthritis: classification, update, and measurement of outcomes. J Orthop Surg Res. 2016 Feb 2;11:19. doi: 10.1186/s13018-016-0346-5. Review. PubMed PMID: 26837951; PubMed Central PMCID: PMC4738796. 6: Baek S, Jo H, Kim H, Kim H, Kim S, Kim D. Highly stereoselective and efficient total synthesis of (+)-laurencin. Org Lett. 2005 Jan 6;7(1):75-7. PubMed PMID: 15624981. 7: Yoshikawa K, Ito T, Iseki K, Baba C, Imagawa H, Yagi Y, Morita H, Asakawa Y, Kawano S, Hashimoto T. Phenanthrene derivatives from Cymbidium Great Flower Marie Laurencin and their biological activities. J Nat Prod. 2012 Apr 27;75(4):605-9. doi: 10.1021/np200788u. Epub 2012 Mar 9. PubMed PMID: 22537363. 8: Laurencin C, Danaila T, Broussolle E, Thobois S. Initial treatment of Parkinson's disease in 2016: The 2000 consensus conference revisited. Rev Neurol (Paris). 2016 Aug - Sep;172(8-9):512-523. doi: 10.1016/j.neurol.2016.07.007. Epub 2016 Jul 29. Review. PubMed PMID: 27476416. 9: Pinn VW, Laurencin CT. The Fight for the Elimination of Racial and Ethnic Health Disparities: Acknowledging the Work and Celebrating the Life of Mr. Louis Stokes. J Racial Ethn Health Disparities. 2015 Dec;2(4):423-4. doi: 10.1007/s40615-015-0168-x. Epub 2015 Sep 28. PubMed PMID: 26863549; PubMed Central PMCID: PMC4750495. 10: Kaneko K, Washio K, Umezawa T, Matsuda F, Morikawa M, Okino T. cDNA cloning and characterization of vanadium-dependent bromoperoxidases from the red alga Laurencia nipponica. Biosci Biotechnol Biochem. 2014;78(8):1310-9. doi: 10.1080/09168451.2014.918482. Epub 2014 Jun 17. PubMed PMID: 25130731. 11: Yu X, Tang X, Gohil SV, Laurencin CT. Biomaterials for Bone Regenerative Engineering. Adv Healthc Mater. 2015 Jun 24;4(9):1268-85. doi: 10.1002/adhm.201400760. Epub 2015 Apr 7. Review. PubMed PMID: 25846250; PubMed Central PMCID: PMC4507442. 12: Ortega N, Martín VS, Martín T. An approach to lauroxanes by iterative use of Co(2)(CO)(6)-acetylenic complexes. a formal synthesis of (+)-laurencin. J Org Chem. 2010 Oct 1;75(19):6660-72. doi: 10.1021/jo101566x. PubMed PMID: 20809659. 13: Laurencin CT. Cato T. Laurencin, MD, PhD. J Natl Med Assoc. 2007 Nov;99(11):1286-7. PubMed PMID: 18020107; PubMed Central PMCID: PMC2574318. 14: Laurencin G. [The long road for psychiatric care in prisons]. Soins Psychiatr. 2016 Mar-Apr;(303):12-4. doi: 10.1016/j.spsy.2016.01.002. French. PubMed PMID: 26948192. 15: Laurencin C, Anheim M, Larrieu L, Tilikete C, Koenig M, Thobois S. Pitfalls in ataxia with ocular motor apraxia type 1: pseudodominant inheritance and very late onset. J Neurol. 2015 May;262(5):1366-8. doi: 10.1007/s00415-015-7717-4. Epub 2015 Apr 7. PubMed PMID: 25845762. 16: Crimmins MT, Emmitte KA. Total synthesis of (+)-laurencin: an asymmetric alkylation-ring-closing metathesis approach to medium ring ethers. Org Lett. 1999 Dec 16;1(12):2029-32. PubMed PMID: 10836060. 17: Loizon M, Laurencin C, Vial C, Danaila T, Thobois S. High incidence of carpal tunnel syndrome after deep brain stimulation in Parkinson's disease. J Neurol. 2016 Dec;263(12):2416-2418. Epub 2016 Sep 13. PubMed PMID: 27624119. 18: Gonem S, Berair R, Singapuri A, Hartley R, Laurencin MFM, Bacher G, Holzhauer B, Bourne M, Mistry V, Pavord ID, Mansur AH, Wardlaw AJ, Siddiqui SH, Kay RA, Brightling CE. Fevipiprant, a prostaglandin D2 receptor 2 antagonist, in patients with persistent eosinophilic asthma: a single-centre, randomised, double-blind, parallel-group, placebo-controlled trial. Lancet Respir Med. 2016 Sep;4(9):699-707. doi: 10.1016/S2213-2600(16)30179-5. Epub 2016 Aug 5. PubMed PMID: 27503237. 19: Lo KW, Kan HM, Gagnon KA, Laurencin CT. One-day treatment of small molecule 8-bromo-cyclic AMP analogue induces cell-based VEGF production for in vitro angiogenesis and osteoblastic differentiation. J Tissue Eng Regen Med. 2016 Oct;10(10):867-875. doi: 10.1002/term.1839. Epub 2013 Nov 6. PubMed PMID: 24493289; PubMed Central PMCID: PMC4497951. 20: Laurencin CT, Nair LS. REGENERATIVE ENGINEERING: APPROACHES TO LIMB REGENERATION AND OTHER GRAND CHALLENGES. Regen Eng Transl Med. 2015 Apr 1;1(1):1-3. Epub 2015 Dec 4. PubMed PMID: 26985451; PubMed Central PMCID: PMC4789288.